Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–69 of 69 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Plasmodium Falciparum Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Malaria Challenge in Healthy Volunteers

NCT01500980
View directory record Official record
Conditions
Malaria
Interventions
P. falciparum infection, Chloroquine, Primaquine
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years

NCT07670377
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
Midazolam (MDZ), GSK3772701
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses

NCT02215707
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine
Biological
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ICC-1132 - Candidate Vaccine Against P Falciparum Malaria

NCT00587249
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Malaria ICC-1132, Alhydrogel
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers

NCT03867331
View directory record Official record
Conditions
Malaria,Falciparum
Interventions
5 microgram VLPM01, 15 microgram VLPM01, 30 microgram VLPM01, Plasmodium falciparum challenge
Biological · Other
Lead sponsor
VLP Therapeutics
Industry
Eligibility
18 Years to 49 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 2, 2026, 3:05 AM EDT
Completed No phase listed Observational

Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia

NCT03996967
View directory record Official record
Conditions
Pneumonia, Bacterial, Viral Infection, Clinical Pneumonia, Plasmodium Falciparum Malaria, Malaria, Infections, Respiratory
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
2 Months to 5 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

NCT00312663
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Falciparum Malaria Protein 11 with AS01B adjuvant.
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Malaria Challenge With NF54 Strain

NCT00744133
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
NF54 P. falciparum isolate
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54

NCT03882528
View directory record Official record
Conditions
Malaria,Falciparum
Interventions
Plasmodium falciparum malaria parasite
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AMA1-C1/Alhydrogel + CpG 7909 for Malaria

NCT00344539
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

NCT00347555
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

NCT01397227
View directory record Official record
Conditions
Malaria
Interventions
Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp), Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine

NCT00427167
View directory record Official record
Conditions
Malaria
Interventions
AMA1-C1/Alhydrogel + CPG 7909 (Saline), AMA1-C1/Alhydrogel + CPG 7909 (Phosphate), AMA1-C1/Alhydrogel + CPG 7909
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 3:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Malaria Clinical Trials Center General Screening

NCT02119312
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 50 Years
Enrollment
2,101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)

NCT01434381
View directory record Official record
Conditions
Malaria
Interventions
Pfs25-EPA/Alhydrogel
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites

NCT03168854
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain, Malaria challenge
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

NCT04072302
View directory record Official record
Conditions
Malaria
Interventions
KAF156, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT06069544
View directory record Official record
Conditions
Malaria
Interventions
BNT165c, BNT165d, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 2, 2026, 3:05 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Malaria CVD 36000; Gates INV090205

NCT07558122
View directory record Official record
Conditions
Malaria (Plasmodium Falciparum)
Interventions
PfSPZ Challenge (NF54), Wearable Biosensor Devices, Placebo
Biological · Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 2, 2026, 3:05 AM EDT
Completed Phase 1 Interventional

Experimental Vaccine for Malaria

NCT00114010
View directory record Official record
Conditions
Malaria
Interventions
AMA1/Alhydrogel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 3:05 AM EDT